Several studies have shown the role of HMGB1 in Parkinson’s disease with respect to dopaminergic neuronal cell death in animal models and, in this context, anti-HMGB1 treatments show a positive response and demonstrate the protective effect on neuronal cell death and blood–brain barrier disruption [132,133]. Here, HMGB1 is linked to Parkinson disease.